<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) August 18, 1997
---------------
BOSTON LIFE SCIENCES, INC.
----------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-6533 87-0277826
- ------------------------------- ------ -------------------------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File No.) Identification No.)
31 Newbury Street, Suite 300
Boston, Massachusetts 02116
- ---------------------------------------- ---------
(Address of principal executive offices) Zip Code
Registrant's telephone number, including area code (617) 425-0200
---------------
<PAGE>
Item 5. Other Events.
-------------
Boston Life Sciences, Inc. announced that it had completed its Phase III trial
for Therafectin(R), its oral drug for the treatment of Rheumatoid Arthritis. The
double-blind, placebo controlled trial enrolled 218 patients at 25 sites in the
U.S. Results are expected to be available within the next six to eight weeks,
after clinical data has been collected from the sites and analyzed.
This trial compared Therafectin to placebo in patients with active Rheumatoid
Arthritis over a 20 week period. The study was designed with very clear
measurable end points, and therefore unambiguous results are expected.
BLSI is engaged in the research and development of novel treatments for cancer,
autoimmune diseases, and central nervous system disorders.
Item 7. Exhibits.
--------
The following Exhibits are filed as part of this report on Form 8-K:
99.1 Press Release, dated August 18, 1997.
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto authorized.
BOSTON LIFE SCIENCES, INC.
Dated: August 28, 1997 By: /s/ Joseph Hernon
----------------------
Joseph Hernon
Chief Financial Officer
<PAGE>
BOSTON LIFE SCIENCES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
Exhibit No. Page
- ----------- ----
99.1 Press Release, dated August 18, 1997 5
<PAGE>
Exhibit 99.1
FOR IMMEDIATE RELEASE
BOSTON LIFE SCIENCES ANNOUNCES THE COMPLETION OF ITS PHASE III
THERAFECTIN TRIAL
Boston, MA -- August 18, 1997--Boston Life Sciences, Inc. (NASDAQ: BLSI)
announced that it has completed its Phase III trial for Therafectin(R), the
Company's oral drug for the treatment of Rheumatoid Arthritis. The double-blind,
placebo-controlled trial enrolled 218 patients at 25 sites in the U.S. Results
are currently expected to be available within the next six to eight weeks, after
clinical data has been collected from the sites and analyzed.
"We are pleased to have completed this pivotal trial, which compared Therafectin
to placebo in patients with active Rheumatoid Arthritis over a 20 week period,"
said Dr. Marc Lanser, Chief Scientific Officer of BLSI. "The study was designed
with very clear measurable end points, and we therefore expect unambiguous
results", added Dr. Lanser.
BLSI is developing novel treatments for cancer, autoimmune diseases, and central
nervous system disorders. In addition to THERAFECTIN, BLSI's products in
clinical trials or in preclinical development include Troponin I, a natural
anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1
(AF-1), a novel central nervous system growth factor; Altropane(TM), a
radioimaging agent for the diagnosis of Parkinson's Disease; and transcription
factors that may control the expression of molecules associated with autoimmune
disease and allergies.
For additional information contact:
Marc E. Lanser, M.D. or S. David Hillson
Chief Scientific Officer President and CEO
617-425-0200 617-425-0200
###
